Influenza--the case for combination therapy.
Krystal
Mark R
MR
Meanwell
Nicholas A
NA
D000998:Antiviral Agents / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control* / Q000821:virology; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D014763:Viral Matrix Proteins / Q000037:antagonists & inhibitors; D000086082:Viroporin Proteins
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D007252:Influenza Vaccines; D009439:Neuraminidase; D014763:Viral Matrix Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins